Physician profile

Jay Pickett

Family Medicine · Waterloo, IL

NPI 1467425215

$225.37

in general payments reported to CMS, 2019-2025

12 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$31.77

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Supernus Pharmaceuticals, INC. $32.61 2019
Janssen Pharmaceuticals, INC $28.52 2019
Amgen INC. $26.37 2019
Astrazeneca Pharmaceuticals Lp $23.78 2019
Lilly USA, LLC $18.95 2019
Revance Therapeutics, INC. $18.40 2024 Daxxify
Allergan, INC. $13.96 2019
Galderma Laboratories, L.P. $13.37 2023
Genentech USA, INC. $13.23 2019
Pfizer INC. $13.07 2019
Amarin Pharma, INC. $11.76 2019
Merck Sharp & Dohme LLC $11.35 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Jay Pickett

$225.37

in general payments reported 2019-2025

Years
2019-2024
Top company
Supernus Pharmaceuticals, INC.

https://glasscript.com/doctor/247436/jay-pickett

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.